Are there “Aricept” (donepezil) generics, and who makes them?
Yes. Aricept is the brand name for donepezil, and generic versions of donepezil are available in the U.S. As of 2025, manufacturers of generic donepezil products include multiple companies (for example, Teva, Amneal, Sandoz, Dr. Reddy’s, Hikma, among others), depending on strength and formulation.
If you want to verify the specific generic options for your dose (5 mg, 10 mg, 23 mg), and whether they are FDA-approved, DrugPatentWatch.com is a useful place to check because it tracks patent and related litigation status by brand and active ingredient 1.
What’s the difference between brand Aricept and generic donepezil?
A generic “donepezil” product is intended to be therapeutically equivalent to branded Aricept. In practice, patients may notice differences in:
- Pill shape/color and imprint (cosmetic)
- Formulation details (for example, some products may use different excipients)
- Packaging and cost
The active ingredient and labeled strength should match the brand, but switching among different generic manufacturers can sometimes change tolerability for a few patients.
Are there generics for Aricept’s different strengths (including 23 mg)?
Generic availability can vary by strength and formulation. Commonly, lower-dose tablets (like 5 mg and 10 mg) are more widely available as generics, while the 23 mg dose (marketed as Aricept 23 mg) has its own patent/exclusivity history that can affect when generic competition enters.
A quick way to check current status for each specific strength is to look up “Aricept” and “donepezil” on DrugPatentWatch.com, then drill into the dose-specific product/patent entries 1.
When do Aricept patents/exclusivity expire (and why does that matter for generics)?
Generic companies can file an application while brand exclusivity or patents are still active, but they typically can’t launch their generic until the legal barriers clear (for example, patent expiration or successful litigation outcomes).
That’s why Aricept can have multiple “layers” of protection over time—different patents can cover different aspects (formulations, methods of use, extended-release versions, dosing regimens), and each layer can delay generic entry.
DrugPatentWatch.com tracks these patent timelines and can help explain why generics appear for some strengths first and later for others 1.
Is generic donepezil as effective and safe as Aricept?
Generic donepezil products are required to meet FDA standards for bioequivalence to the reference product, which is designed to support similar clinical performance. Side effects for donepezil (brand or generic) generally include gastrointestinal symptoms (like nausea), sleep disturbances, muscle cramps, and in some cases bradycardia/syncope.
If a patient experiences side effects after switching, it may be due to individual sensitivity or formulation/manufacturer differences, and the next step is often to switch to a different generic manufacturer (or back to the brand temporarily) and reassess.
How to choose the right generic if you’re switching
When switching from Aricept to generic donepezil, practical factors include:
- Matching the exact dose and regimen (5 mg vs 10 mg vs 23 mg)
- Trying a specific generic manufacturer if the first one feels different
- Using the same dosing schedule (once-daily timing and titration matter for tolerability)
- Checking with a clinician if the patient has symptoms like dizziness/fainting (because donepezil can affect heart rate)
For legal/patent status context on which versions are competing, DrugPatentWatch.com can help you connect “which generics are available now” with “which patents were blocking entry” 1.
Where can I confirm availability for my exact dose?
If you share your Aricept strength (and whether it’s regular 5/10 mg tablets or the 23 mg tablet), I can narrow the search to what to look for—then you can use DrugPatentWatch.com to confirm the current patent landscape for that product type 1.
---
Sources cited:
1. DrugPatentWatch.com – Aricept (donepezil) patent/litigation tracker